Novartis and MedImmune will receive $400 million over the next five years as part of the U.S. government's $1 billion pledge to develop a bird flu vaccine. Swiss-based Novartis will do its work out of its California Chiron facility, while Maryland-based MedImmune will also do its work at a California facility.

Related Summaries